Transplant News and Research

RSS

BioScrip reports revenues of $333.5 million for the third quarter of 2009

BioScrip, Inc. today announced third quarter net income of $5.7 million, or $0.14 per diluted share, on revenues of $333.5 million. These results compare to net income of $1.4 million, or $0.04 per share, on revenues of $359.4 million for the third quarter of 2008. Third quarter 2009 EBITDAO was $8.9 million compared to $5.3 million for the same period a year ago.

30 Oct 2009

UT Southwestern ophthalmologist receives 2009 Castroviejo Medal

Dr. H. Dwight Cavanagh, vice chairman of ophthalmology at UT Southwestern Medical Center, has been named the 2009 recipient of the prestigious Castroviejo Medal, one of the top ophthalmology prizes in the world.

30 Oct 2009

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors.

30 Oct 2009

Pre-dialysis recipients with high kidney function do not benefit from kidney transplants

Pre-dialysis transplant recipients with a high level of kidney function don't benefit from their transplant more than pre-dialysis recipients with low level kidney function, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

Women face higher risk of graft loss after liver transplantation compared to men

Although women with chronic hepatitis C virus (HCV) infection are at lower risk for developing cirrhosis, researchers who compared outcomes for men and women after having liver transplantation found that women have a significantly increased risk of overall graft loss and graft loss from recurrent HCV than men.

30 Oct 2009

Absence of male hormones extends transplanted cell survival, says new study

Trophoblast stem cells (TSCs), cells found in the layer of peripheral embryonic stem cells from which the placenta is formed, are thought to exhibit "immune privilege" that aids cell survivability and is potentially beneficial for cell and gene therapies. Further, the survivability of TSCs has been thought to require the presence of ovarian hormones. However, none of these assumptions has ever been verified.

30 Oct 2009

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

Kidney transplant consent forms are often written at a level that makes it difficult for many kidney patients to fully understand them, according to a paper being presented at the American Society of Nephrology's annual meeting in San Diego, CA. The study findings indicate that consent forms are written on average at a 12th-grade reading level, but to ensure all patients fully comprehend treatment options should be prepared at a 5th - 8th grade reading level.

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

Legislation on Assisted Reproductive Technology proposed by the ICMR discussed

Vinay Menon of Mumbai, India-based law firm Menon & Associates (www.menonlawassociates.com) and Indian Counsel for Proactive Family Solutions was among the panel speakers on this topic at the Fall Conference of the American Bar Association Section of Family Law recently held in Montreal, Canada.

29 Oct 2009

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Brain cell transplants help replace degenerated neurons, finds Swiss research team

A Swiss research team has found that using an animal's own brain cells (autologous transplant) to replace degenerated neurons in select brain areas of donor primates with simulated but asymptomatic Parkinson's disease and previously in a motor cortex lesion model, provides a degree of brain protection and may be useful in repairing brain lesions and restoring function.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

Rennes University Hospital surgeons undergo training for the SynCardia CardioWest Total Artificial Heart

On Oct. 26 & 27, the surgical team from Rennes University Hospital, led by Dr. Erwan Flecher and Prof. Jean-Philippe Verhoye, completed the first phase of certification training for the SynCardia temporary CardioWest™ Total Artificial Heart in Paris. The team trained exclusively with the new Companion Driver System, which received the CE Mark to power the Total Artificial Heart in Europe on Oct. 13.

28 Oct 2009

Multidisciplinary center to be launched for treatment of advanced liver disease

Distinguished transplant and cancer surgeon, Alan Hemming, MD, has been recruited to the University of California, School of Medicine to launch a multidisciplinary center for the treatment of advanced liver disease at the UC San Diego Medical Center and Moores UCSD Cancer Center.

28 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

27 Oct 2009

Patient receives left-ventricular assist device to improve heart function

UT Southwestern Medical Center patient Michael LeBlanc, 40, is the first in North Texas to receive the newest generation of a mechanical device designed to improve heart function. It will be his lifeline while he awaits a heart transplant.

27 Oct 2009

Donor testing services from LABS

LABS Inc., one of the premier transplant reference and consultative laboratories in the country, announced today that it will begin offering a full range of donor testing services to the transfusion medicine and blood services industry. LABS Inc.'s acquisition of Research and Diagnostic Laboratories in October brings its expertise to blood collection programs nationwide.

27 Oct 2009

Transplant News and Research

BioScrip reports revenues of $333.5 million for the third quarter of 2009

UT Southwestern ophthalmologist receives 2009 Castroviejo Medal

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Pre-dialysis recipients with high kidney function do not benefit from kidney transplants

Women face higher risk of graft loss after liver transplantation compared to men

Absence of male hormones extends transplanted cell survival, says new study

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

Legislation on Assisted Reproductive Technology proposed by the ICMR discussed

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Brain cell transplants help replace degenerated neurons, finds Swiss research team

Moores UCSD Cancer Center awarded $20 million for cancer research

Pure Protein develops soluble Class II human leukocyte antigens

Global sales volumes of Levulan Kerastick exceed one million units

Rennes University Hospital surgeons undergo training for the SynCardia CardioWest Total Artificial Heart

Multidisciplinary center to be launched for treatment of advanced liver disease

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

Patient receives left-ventricular assist device to improve heart function

Donor testing services from LABS

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News